| Literature DB >> 29077028 |
Luke Stanaway1, Kay Rutherfurd-Markwick2,3, Rachel Page4,5, Ajmol Ali6,7.
Abstract
Supplementation with nitrate (NO₃-)-rich beetroot juice has been shown to improve exercise performance and cardiovascular (CV) responses, due to an increased nitric oxide (NO) availability. However, it is unclear whether these benefits are greater in older adults who have an age-related decrease in NO and higher risk of disease. This systematic review examines 12 randomised, crossover, control trials, investigating food-based NO₃- supplementation in older adults and its potential benefits on physiological and cognitive performances, and CV, cerebrovascular and metabolic health. Four studies found improvements in physiological performance (time to exhaustion) following dietary NO₃- supplementation in older adults. Benefits on cognitive performance were unclear. Six studies reported improvements in CV health (blood pressure and blood flow), while six found no improvement. One study showed improvements in cerebrovascular health and two found no improvement in metabolic health. The current literature indicates positive effects of dietary NO₃- supplementation in older adults on physiological performance, with some evidence indicating benefits on cardiovascular and cerebrovascular health. Effects on cognitive performance were mixed and studies on metabolic health indicated no benefit. However, there has been limited research conducted on the effects of dietary NO₃- supplementation in older adults, thus, further study, utilising a randomised, double-blind, control trial design, is warranted.Entities:
Keywords: beetroot juice; blood pressure; cardiovascular; cognition; nitric oxide; older adults
Mesh:
Substances:
Year: 2017 PMID: 29077028 PMCID: PMC5707643 DOI: 10.3390/nu9111171
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Flowchart showing study selection procedure and results.
Summary of studies investigating the effects of dietary nitrate supplementation on physical performance, cognitive performance, and health-based outcomes in older adults.
| Reference | Participants | Study Design | Supplementation Protocol | Testing Protocols | Blood Measures (NO Indices) | Physiological Performance Outcomes | Cognitive Performance Outcomes | Health-Based Outcomes |
|---|---|---|---|---|---|---|---|---|
| Berry et al., 2015 [ | 15 COPD patients (m/f 12/3) (age 69.6 ± 8.5) | Randomised, single-blind crossover | Acute supplementation, 2.5 h prior to exercise, 140 mL BR (7.58 mmol NO3]) (Note PL used was prune juice) | Constant work rate test at 75% max on cycle ergometer | ↑ Plasma [NO2−] | ↑ Time to exhaustion during submaximal cycle exercise | NT | ↓ SBP |
| Eggebeen et al., 2016 [ | 20 HFpEF patients (m/f 3/17) (age 69 ± 7) | Randomised, double-blind crossover | Phase 1: Acute supplementation, 1.5–2 h prior to exercise, 70 mL BR (6.1 mmol NO3−) | Constant work rate test at 75% max on cycle ergometer | ↑ Plasma [NO2−] | ↑ Time to exhaustion during submaximal cycle exercise | NT | ↓ SBP |
| Kenjale et al., 2011 [ | 4 male and 4 female PAD patients (age 67 ± 13) | Randomised, open-label, crossover | Acute supplementation, 3 h prior to exercise, 500 mL BR (9 mmol NO3−) (Note: orange juice was used as PL) | Walking maximal cardiopulmonary exercise (CPX) test | ↑ Plasma [NO2−] | ↑ Walking duration longer before onset of pain (18%) | NT | ↑ Tissue blood flow (NIRS) |
| Siervo et al., 2016 [ | 19 healthy older adults (m/f 9/10) (age 64.7 ± 3) | Randomised, double-blind crossover | 7 days supplementation, 2 × 70 mL·day−1 BR (12 mmol·day−1 NO3−) | Incremental cycle test to voluntary exhaustionHand-grip strength testTime up-and-go testRepeated chair raising test10-m walking test | ↑ Plasma [NO3−] | ↔ O2 consumption | NT | ↔ BP |
| Kelly et al., 2013 [ | 6 male and 6 female older adults (age 64 ± 4; 63 ± 2) | Randomised, double-blind crossover | 3 days supplementation, 140 mL·day−1 BR (9.6 mmol·day−1 NO3−) | Walking treadmill test and leg ergometer. Cognitive function tests | ↑ Plasma [NO2−] | ↓ | ↔ Cognitive tests | ↓ SBP |
| Gilchrist et al., 2014 [ | 27 older adults with type 2 diabetes (m/f 18/9) (age 67.2 ± 4.9) | Randomised, double-blind crossover | 14 days supplementation, 250 mL·day−1 BR (7.5 mmol NO3−) | 5 cognitive tests on E-Studio software | ↑ Plasma [NO2−] | NT | ↓ Simple reaction time (improvement) | NT |
| Presley et al., 2011 [ | 14 healthy older adults (sex not stated) (age 74.7 ± 6.9) | Placebo-controlled, crossover | 2 days high NO3− diet with BR (~12.4 mmol NO3−) | NT | ↑ Plasma [NO2−] | NT | NT | ↑ Cerebral perfusion (MRI) |
| de Oliveira et al., 2016 [ | 20 older adults with risk factors for cardiovascular disease (m/f 7/13) (age 70.5 ± 5.6) | Randomised, double-blind crossover | Acute supplementation, 2 h prior to measurements, 100 g BG (12.2 mmol NO3−) (PL used was NO3− depleted gel) | NT | ↑ Urinary [NO2−] | NT | NT | ↑ Endothelial function |
| Gilchrist et al., 2013 [ | 27 older adults with type 2 diabetes (m/f 18/9) (age 67.2 ± 4.9) | Randomised, double-blind crossover | 14 days supplementation, 250 mL·day−1 BR (7.5 mmol NO3−) | NT | ↑ Plasma [NO2−] | NT | NT | ↔ BP |
| Kemmner et al., 2017 [ | 17 older adults with CKD (m/f 7/10) (age 72 ± 6) | Randomised, open-label crossover | Acute supplementation, 4 h prior to repeat measures, 200 mL BR (300 mg NO3−) (Note PL used was water) | Hemodynamic parameters and renal resistance index measure | ↑ Plasma [NO3−] | NT | NT | ↓ SBP |
| Miller et al., 2012 [ | 8 normotensive older adults (m/f 3/5) (age 72.5 ± 4.7) | 4-arm, randomised, crossover | 3 days low NO3− diet (0.70 mmol NO3−) | NT | ↑ Plasma [NO2−] | NT | NT | ↔ BP |
| Shepherd et al., 2016 [ | 15 healthy older adults (m/f 8/7) (age 59.2 ± 6) | Randomised, double-blind crossover | Acute supplementation, 140 mL BR (11.91 mmol [NO3−]) | NT | ↑ Plasma [NO2−] | NT | NT | ↔ BP |
All values are mean ± SD. ↑ significant increase;↓ significant decrease; ↔ no significant difference; m/f, males/females; NT, not tested; [NO2−], nitrite concentration; [NO3−], nitrate concentration; BR, beetroot juice; PL, placebo; BG, beetroot gel; BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; RRI, renal resistive index; , oxygen uptake; HR, heart rate; NIRS, near infrared spectroscopy; MRI, magnetic resonance imaging; COPD, chronic obstructive pulmonary disease; HFpEF, heart failure with preserved ejection function; CKD, chronic kidney disease; PAD, peripheral arterial disease.